Current advance in the application of anti-vascular endothelial growth factor drugs in wet age-related macular degeneration

Guoji Yanke Zazhi

卷:20

Ling-Yi Ouyang¹  Yi-Qiao Xing¹ 

[1] Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China;

关键词: anti-vascular endothelial growth factor;    wet age-related macular degeneration;    choroidal neovascularization;   

DOI  :  10.3980/j.issn.1672-5123.2020.1.17

来源: DOAJ

【 摘 要 】

Age-related macular degeneration(ARMD)is one of the main causes which lead to irreversible blindness. Wet ARMD, which is featured by choroidal neovascularization(CNV), takes up 90% in ARMD related blind patients. With the increasing population of aged people in China, wet ARMD has become a severe social and medical issues. Currently, management aiming at wet ARMD is the applications of anti-VEGF agents. Anti-VEGF drugs not only postpone the development of CNV, but also preserve the visual function, improve the prognosis, and reduce the incidence of blindness. However, we still need to focus on the non-response during treatment, long-term maintenance, drug resistance, adverse reactions, and economic effectiveness. Here we review the recent clinical medications on wet ARMD.

【 授权许可】

Unknown